Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SRP 001

Drug Profile

SRP 001

Alternative Names: SRP 3D (diethylamide); SRP-001; SRP-3D-(DA)

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator South Rampart Pharma
  • Class Acetanilides; Aminophenols; Analgesics; Antipyretics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Cyclo-oxygenase 2 inhibitors; Cytochrome P 450 enzyme system inhibitors; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 02 Jan 2024 Adverse events and pharmacokinetics data from a phase I trial in Pain released by South Rampart Pharma
  • 02 Jan 2024 South Rampart Pharma completes a phase I trial in Pain (In volunteers) in USA (PO) (NCT05484414)
  • 01 Nov 2023 South Rampart Pharma has patent protection for compositions and methods for ameliorating pain including SRP 001 and other compounds in USA, EU, China, Hong Kong, Japan, India, Australia, South Korea, Canada, Brazil, Russia, and Mexico
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top